platoseedplatoseed
Curative genetic medicines for kidney diseases
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Nephrogen is a Stanford biotech spinout focused on curative genetic medicines for kidney and pancreatic diseases. It commercializes an AI-driven screening platform to design and validate tissue-specific gene delivery vehicles to enable curative genetic therapies.
Nephrogen uses the NeFIND platform, an AI screening system that combines artificial intelligence with high-throughput in vivo screening to design delivery vehicles with tissue-specific tropism. The platform aims to identify adeno-associated viral (AAV) delivery vehicles that are more efficient, cheaper, and less immunogenic, enabling gene therapies for kidney and pancreatic diseases. It addresses delivery bottlenecks by discovering vehicles that improve targeting and performance in relevant tissues.
Who it’s for: Biotech startups and pharmaceutical companies developing gene therapies, academics and research institutions seeking kidney/pancreas-targeted genetic medicines, and potential partners in delivery vehicle discovery.
Hiring and leadership profiles; mention of ongoing research and advisory involvement; indicates early-stage biotech startup activity and ongoing development
No founder data available for this company.
AI platform accelerating therapies for rare & inflammatory diseases.
Using CRISPR to find treatments for cancer and inflammation
